The purpose of this study is to study the possible drug-drug interactions between ceftiofur sodium and rantidine on co-administration. These studies have been carried out at normal as well as the elevated temperature at pH corresponds to full gut (pH = 7.4). The spectrophotometric method has been used to study the bioavailability studies of each drug individually and in the presence of the other drug. Change in the bioavailability of ceftiofur sodium in the presence of ranitidine as compared to the bioavailability in the absence of rantidine supported the possible interactions between the two drugs.
INTRODUCTION
Ceftiofur sodium is a third-generation cephalosporin having strong antibiotic activity which can kill bacteria and some anaerobe. It possesses broad-spectrum activity against both types of bacteria i.e. grampositive as well as gram-negative. 1 In a similar fashion to that of other cephalosporins, its antibiotic activity results from the inhibition of mucopeptide synthesis in the cell wall. It has worldwide approval for respiratory disease ruminants, horses and swine. IUPAC name of ceftiofur sodium is (6R,7R)-7-[[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(furan-2-carbonyl sulfanylmethyl) -8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid. It's stabilized molecular structure which cannot be destroyed by β-lactamase ( Fig.-1) . It is reported to form metal complexes which act as better antibacterial agents. 2 The use of cephalosporins is associated with the risk of gastrointestinal complications. Therefore coadministration of the acid suppressant drugs like H 2 -receptor antagonist is usually prescribed along with the cephalosporins. 3 But it is well established in literature that the simultaneous administration of one drug in the presence of the other may lead to drug-drug interactions which may affect the pharmacokinetic properties of the interacting drugs. Numbers of reports are available in literature where cephalosporins are known to interact with probenecids [4] [5] , alcohols [6] [7] [8] [9] , cholestyramines 10 , theophylines 11 , aminoglycosidic antibiotics 12 and anticoagulants 13 . The cephalosporins like cephalexin 14 , Cefetamet pivoxil 15 , Cefixime 16 and cefpodoxime proxetil 17 are also known to interact with H 2 -receptor antagonists. H 2 -receptor antagonists have been assayed by various methods in literature. [18] [19] In the present study, an attempt has been made to study the effect of simultaneous administration of ranitidine and ceftiofur sodium on the bioavailability of each drug at 7.4 pH (which corresponds to full gut pH) at normal as well as elevated temperature by using spectrophotometer.
EXPERIMENTAL
Analytical grade chemicals were used for the proposed study and were purchased from Merck. Reference standard tablet formulation rantidine.HCl (150mg, Zantac, Glaxo SmithKline) and ceftiofur sodium (250mg, Naxcel, Pfizer, Inc.) were purchased from the local pharmacy. Reference standards of ceftiofur sodium and cimetidine were obtained from Mcleods pharmaceuticals, Mumbai, as a gift. All the solutions were prepared by using double distilled water. An absorbance study was done by using Shimadzu UV-1800ENG240V1 spectrophotometer.
Preparation of Phosphate Buffer of pH=7.4
Disodium hydrogen phosphate (17.90 gm) was dissolved in double-distilled water and the total volume was made to 500 ml in volumetric flask. In another volumetric flask, potassium dihydrogen phosphate (6.80 gm) was dissolved in double-distilled water and the total volume was made to 100ml. For the preparation of 1 liter of the required buffer solution, disodium hydrogen phosphate (31.4 ml) and potassium dihydrogen phosphate (5.7 ml) solutions were dissolved in 1 liter of double distilled water in 1liter volumetric flask. Few drops of disodium hydrogen phosphate were used to achieve required pH of 7.4.
Preparation of Solution of Ceftiofur Sodium and Ranitidine Preparation of Stock Solutions
To prepare 1 mmol/L of stock solution, 0.035 gm of the reference standard of ranitidine and 0.055gm of reference standard of ceftiofur sodium were dissolved in 100 ml of phosphate buffer solution in 100 ml volumetric flasks separately.
Preparation of Working Standard Solutions
1 to 20 ml of the stock solutions were taken in the 100 ml volumetric flasks separately and the total volume was made to 100 ml by using phosphate buffer solution in each case to obtain the working standard solutions from 0.01 mmol to 0.2 mmol.
Calculation of λ max for Ceftiofur Sodium and Ranitidine
The λ max of each reference standard was measured at 0.001mmol of concentration which was prepared by dilution of 1ml of stock solution to 100 ml by the use of phosphate buffer solution.
Calibration Curve for Ceftiofur Sodium and Ranitidine
To establish the working concentration range for the proposed study, the validation of the Beer-Lambert law was done. For this, the absorption maxima of the working standard solutions of each drug were measured in the UV region against region blank. Further, the samples of ceftiofur sodium were scanned at the wavelength of its absorption maxima and at the absorption maxima of the ranitidine. In the same way, the samples of ranitidine were scanned at the wavelength of its absorption maxima and at the absorption maxima of ceftiofur sodium. The graphs (FigS.-2 to 5) of concentration Vs absorption maxima were plotted which gave rise to straight-line confirming the linearity of Beer-Lambert law. Further, molar absorptivity (ε) values were obtained by using equation 
Studies of Bioavailability of Ceftiofur Sodium and Ranitidine
A known amount of tablet formulation of each drug was poured into 1 liter of buffer solution maintained at specific temperature (37 o C and 60 o C). The aliquots were drawn after every 15 minutes till 240 minutes and were analyzed for the drug content by using equation-2. The total volume of the solution was kept constant by addition of same volume of buffer solution maintained at the same temperature as the aliquots were withdrawn. %age of drug dissolved = (c/x) x 100 (2) Where c = concentration obtained from equation-1 x = amount of the drug dissolved
Interaction of Ceftiofur Sodium with Ranitidine
The interaction studies between ceftiofur sodium and ranitidine were done at 37 o C and 60 o C. For this, the tablet formulation of ceftiofur sodium was added into 1 liter of buffer solution at zero time and tablet formulation of ranitidine was added to the dissolution medium after 15 minutes. Aliquots were withdrawn after every 15 minutes till 240 minutes and were assayed for the concentration of each drug by using equations 3-4.
Where, C a is the concentration of a sample of ceftiofur sodium C b is the concentration of ranitidine ε a and ε b correspond to the molar absorptivities values of ceftiofur sodium and ranitidine at 293nm ε a' and ε b' correspond to the molar absorptivities of ceftiofur sodium and ranitidine at 232nm
RESULTS AND DISCUSSION λ max of Ceftiofur Sodium and Ranitidine
To calculate the λ max ranitidine hydrochloride and ceftiofur sodium, 0.001 mmol solutions of each drug were scanned from 150-400 nm. A strong absorption maxima was obtained at 232 nm for ranitidine and at 293 nm for ceftiofur sodium.
The linearity of Beer-Lambert Law
To obtain the working concentration range for each drug to determine the dug-drug interaction, the linearity of the Beer-Lambert law was established. For this purpose, the working standard solutions of each drug were subjected to spectrophotometric analysis at their respective absorption maxima as well as at the absorption maxima of the other drug. 
Molar Absorptivity (ε) Studies for Ceftiofur Sodium and Ranitidine Hydrochloride
The results obtained from Beer-Lambert law were further used to calculate the ε values of Ranitidine hydrochloride and Ceftiofur sodium which are presented in Table-3 and Table- respectively. 
Bioavailability Studies
The ε values calculated in Table-3 and Table-4 were used further for the bioavailability studies of each drug at 7.4 pH at 37 o C and 60 o C which the results of which are produced in Table-5 and Table-6 for Ceftiofur sodium and Rantidine hydrochloride respectively. 
Interaction Studies Ceftiofur Sodium and Ranitidine Hydrochloride
The results of interaction studies of Ceftiofur sodium and Rantitidine hydrochloride are summarized in Table-7 and Table-8 at 37 o C and 60 o C respectively. 
Establishment of Beer-Lambert Law
The graphical representations of the results obtained in Table  Ranitidine hydrochloride 
Bioavailability Study of Ceftiofur Sodium
The bioavailability studies of Ceftiofur sodium at 37 clear from the studies that at 37 o C, 91% of the bioavailab 93% as the maximum value after 45 minutes. The decrease in bioavailability was observed post 15 minutes where minimum of 82% bioavailability was observed after 240 minutes. This decrease in the bioavailability of Ceftiofur sodium with increase in time may be attributed to the degradation of the drug 
Lambert Law
The graphical representations of the results obtained in Table-1 and Table-2 
Bioavailability Study of Ceftiofur Sodium
The bioavailability studies of Ceftiofur sodium at 37 o C and 60 o C is presented in Figure  C , 91% of the bioavailability was obtained after 15 minutes and attains 93% as the maximum value after 45 minutes. The decrease in bioavailability was observed post 15 minutes where minimum of 82% bioavailability was observed after 240 minutes. This decrease in the y of Ceftiofur sodium with increase in time may be attributed to the degradation of the drug 2 for Ceftiofur sodium and 5 respectively. It is well clear from Lambert law within the odium C is presented in Figure-6 at 293 nm. It is ility was obtained after 15 minutes and attains 93% as the maximum value after 45 minutes. The decrease in bioavailability was observed post 15 minutes where minimum of 82% bioavailability was observed after 240 minutes. This decrease in the y of Ceftiofur sodium with increase in time may be attributed to the degradation of the drug 0.25 in buffer solution of pH= 7.4 [20] . On the other hand at 60 15 minutes which then decreases with time and attained a minutes. The studies show that the increase in the temperature results in quick release of Ceftiofur sodium but it also assist the degradation of the drug with time to a greater extent as compared to degradation at lower temperature. in buffer solution of pH= 7.4 [20] . On the other hand at 60 o C, the bioavailability 94% was observed after 15 minutes which then decreases with time and attained a minimum bioavailability of 79% after 240 minutes. The studies show that the increase in the temperature results in quick release of Ceftiofur sodium but it also assist the degradation of the drug with time to a greater extent as compared to degradation at C, the bioavailability 94% was observed after minimum bioavailability of 79% after 240 minutes. The studies show that the increase in the temperature results in quick release of Ceftiofur sodium but it also assist the degradation of the drug with time to a greater extent as compared to degradation at odium ydrochloride ydrochloride 0.25 0.25
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The graphical representation of bioavailability studies of Ranitidine hydrochloride 7. At 37 o C, the drug achieves bioavailability of 86% after 15 minutes and attains maximum value of 99% after 135 minutes. Post 135 minutes, the bioavailability remains almost same and reaches 100% after 2409 minutes. Further, increase in temperature results in quic bioavailability after 15 minutes. The s minutes after which the increase in temperature does not bioavailability was achieved. (Figure-9 ), ceftiofur sodium shows maximum bioavailabili minutes. Further, the presence of Ranitidine hydrochloride assists the quick release of ceftiofur sodium attaining value of 98% as compared to 94% of release in the case of ceftiofur sodium alone. Further, ceftiofur sodium shows better availability in the presence of Ranitidine hydrochloride till 120 minutes after which the bioavailability starts decreasing as compared to ceftiofur sodium alone reaching to minimum value of 59% in the presence of Ranitidine hydrochl 79% bioavailability in the case of ceftiofur sodium alone. The graphical representation of bioavailability studies of Ranitidine hydrochloride is presented in Figure  C , the drug achieves bioavailability of 86% after 15 minutes and attains maximum value of 99% after 135 minutes. Post 135 minutes, the bioavailability remains almost same and reaches 100% after 2409 minutes. Further, increase in temperature results in quick release of the drug with 95%
The same bioavailability was achieved at both the temperatures after 120 minutes after which the increase in temperature does not affect the release of the drug and same 6 : Bioavailability Study of Ceftiofur Sodium Bioavailability of Ranitidine Hydrochloride at 232 nm Ranitidine Hydrochloride Interactions 8 depicts the bioavailability study of Ceftiofur sodium in the absence and presence of Ranitidine C. It can be inferred from the figure that till 30 minutes, the presence of Ranitidine hydrochloride assists the release of Ceftiofur sodium. Post 30 minutes, ceftiofur sodium is less available presence of Ranitidine hydrochloride attaining a minimum value of approximately 70% after 240 minutes as compared to approximately 90% of bioavailability of ceftiofur alone. On the other hand at 9), ceftiofur sodium shows maximum bioavailability at the start of the experiment after 15 minutes. Further, the presence of Ranitidine hydrochloride assists the quick release of ceftiofur sodium attaining value of 98% as compared to 94% of release in the case of ceftiofur sodium alone. Further, ur sodium shows better availability in the presence of Ranitidine hydrochloride till 120 minutes after which the bioavailability starts decreasing as compared to ceftiofur sodium alone reaching to minimum value of 59% in the presence of Ranitidine hydrochloride after 240 minutes as compared to the 79% bioavailability in the case of ceftiofur sodium alone. presented in Figure-C, the drug achieves bioavailability of 86% after 15 minutes and attains maximum value of 99% after 135 minutes. Post 135 minutes, the bioavailability remains almost same and reaches 100% after k release of the drug with 95% ame bioavailability was achieved at both the temperatures after 120 ffect the release of the drug and same absence and presence of Ranitidine C. It can be inferred from the figure that till 30 minutes, the presence of Ranitidine hydrochloride assists the release of Ceftiofur sodium. Post 30 minutes, ceftiofur sodium is less available minimum value of approximately 70% after 240 minutes as compared to approximately 90% of bioavailability of ceftiofur alone. On the other hand at ty at the start of the experiment after 15 minutes. Further, the presence of Ranitidine hydrochloride assists the quick release of ceftiofur sodium attaining value of 98% as compared to 94% of release in the case of ceftiofur sodium alone. Further, ur sodium shows better availability in the presence of Ranitidine hydrochloride till 120 minutes after which the bioavailability starts decreasing as compared to ceftiofur sodium alone reaching to oride after 240 minutes as compared to the Till 45 minutes, the drug shows more availability at elevated temperature trend reverses after 45 minutes, with drug being lesser available at higher temperature temperatures. After 240minutes it is observed that 59% of ceftiofur sodium is available at 60°C in comparison to 67% at 37°C. The results found are in accordance with those reported for cephr Till 45 minutes, the drug shows more availability at elevated temperatures than normal temperature. The trend reverses after 45 minutes, with drug being lesser available at higher temperature After 240minutes it is observed that 59% of ceftiofur sodium is available at 60°C in comparison to 67% at 37°C. The results found are in accordance with those reported for cephr 10 shows the comparison of bioavailability studies of ceftiofur sodium in the presence of ranitidine at 37°C and 60°C. It is observed that at both temperatures, the availability of the drug decreases than normal temperature. The trend reverses after 45 minutes, with drug being lesser available at higher temperatures than at lower After 240minutes it is observed that 59% of ceftiofur sodium is available at 60°C in comparison to 67% at 37°C. The results found are in accordance with those reported for cephradine- ranitidine interactions 21 where the availability of cephradine was found to increase at the beginning of the experiment and then decrease as compared to the availability of the drug in the absence of ranitidine.
CONCLUSION
It is well established from the results that the presence of Ranitidine hydrochloride does affect the bioavailability of Ceftiofur sodium at moderate and elevated temperatures. Further, the presence of Ranitidine hydrochloride assists the quick release of Ceftiofur sodium at the start of the experiment at both temperature but after some time interval the bioavailability of Ceftiofur sodium was found to decrease in the presence of Ranitidine hydrochloride. This may be attributed to the possible formation of new intermediate due to drug-drug interactions which absorb at different wavelength eventually leading to change in the bioavailability of ceftiofur sodium in the presence of Ranitidine hydrochloride.
